We're delighted to feature in @thisismoney in today's @MailOnline . SMALL CAP IDEA: Ketamine drip therapy firm is taking on alcoholism. Covers our #AUD (SVN-001 & SVN-002) and #PTSD (SVN-SDN-14) prgrms. 🔗 @proactive_x @ProfDavidNutt @AnthonyTennyson.

Our CEO, @AnthonyTennyson, cuaght up with @ZaksTradersCafe earlier today to provide details on our recent progress in drug discovery for #PTSD and drug development for #AUD . 👂have a listen!. @SolvonisTx @ProfDavidNutt.

Our CEO, @AnthonyTennyson, sat down with the @RoastPR team this morning . Have a listen.

Proud of our team + partners providing hope in PTSD treatment. Follow our journey: @Solvonis . @PTSDAlliance @PTSDUK @HeadwayUK @MindCharity @ProfDavidNutt . #PTSD #MentalHealthAwareness #HopeThroughScience #NeuroInnovation.

Positive results enable us to advance SVN-SDN-14 towards in vivo studies. #clinicaltrials #TranslationalMedicine #DrugDevelopment #BiotechInvesting #LifeSciences. @ProfDavidNutt @ClinicalTrialsGov @NatureMedicine @ScienceTM @Medscape.

SVN-SDN-14 - a novel small molecule series, designed to address unmet needs in PTSD — an area where current options remain limited. #PTSDResearch #MentalHealth #Innovation #DrugDevelopment. @NIH @WHO @MHInnovation @DARPA @DeptVetAffairs @ProfDavidNutt.

🚀 Positive preclinical results for SVN-SDN-14 in PTSD today. Robust SERT, DAT, NET modulation. Major milestone towards new PTSD therapies. #PTSD #Biotech #DrugDiscovery #BiotechNews . @FierceBiotech @EndpointsNews @NatureBiotech @ProfDavidNutt.

PTSD isn’t just psychological — it’s neurological. Trauma affects serotonin, dopamine & noradrenaline pathways — disrupting mood, memory & stress response. @Solvonis is targeting these systems. #PTSD #Neurobiology #CNSBiotech #Solvonis $SVNS

Over 300M people will experience #PTSD in their lifetime. Yet first-line treatments fall short. @SolvonisTx (LSE: SVNS) is developing new medicines for chronic, high-prevalence diseases like PTSD — where effective options remain limited. #MentalHealth #Solvonis.

Solvonis (LSE: SVNS) is aligned with the neuropsychiatry market reset. - ATAI, CMPS, MNMD, GHRS up 35–75%.- Spravato hits $1.3B run rate.- RFK Jr. calls for FDA reform. $SVNS Clinically active, capital disciplined, CNS-focused. #Biotech #CNS #AUD #PTSD #505b2 #SVNS #MentalHealth.

Solvonis (LSE: SVNS) is advancing SVN‑002, a sublingual esketamine OTF, for mod.-to-severe AUD — ~66% of the 29M US cases - targeting 505b2 to Spravato. Spravato, approved for TRD (~4–6M), hit $320M Q2 sales. J&J now guiding $3B–$3.5B peak. 📈 Bigger need. Clear precedent.

Solvonis is advancing SVN‑002 under the FDA’s 505(b)(2) pathway, referencing J&J’s $1B+ blockbuster Spravato®. SVN‑002 targets moderate-to-severe #AUD with a differentiated formulation for addiction clinics. #SVN002 #505b2 #Spravato #AddictionTreatment #Solvonis $SVNS

AUD is the crisis we keep ignoring. 29.5M Americans meet criteria for AUD. <5% get treatment. SVN‑002 is our neuroscience-led response:. ✔ Novel esketamine therapeutic .✔ Clinic-based .✔ 505(b)(2) path, bridging to Spravato®. #AUD #SVN002 #505b2 #AddictionTreatment #Solvonis

Congrats to @SolvonisTx Chair, Dennis Purcell, on landmark $1.9B @AbbVie–IGI deal. As a Board Director at IGI, he played a key role in one of biotech’s biggest licensing agrmnts of 2025. 🔹$700M upfront 🔹$1.225B in milestones 🔹Tiered royalties.Proud to have him lead Solvonis.

29.5M Americans meet criteria for #AlcoholUseDisorder. Just 5% receive treatment. Time for a new paradigm. SVN‑002 is @SolvonisTx neuroscience-based response — designed for real-world clinical delivery in the #US. #AUD #505b2 #AddictionTreatment #Solvonis

Severe #AUD is one of hardest to treat mental health conditions. SVN‑001 - a novel combo of racemic ketamine + psychotherapy - is designed 2 support durable recovery. 86% abstinence @ 6 months in Ph 2 Now in Ph 3 (n=280) in NHS England, targeting UK + EU mrkt apprvl. $SVNS

Severe #AUD is one of hardest to treat mental health conditions. SVN‑001 - a novel combo of racemic ketamine + psychotherapy - is designed 2 support durable recovery. 86% abstinence @ 6 months in Ph 2.Now in Ph 3 (n=280) in NHS England, targeting UK + EU mrkt apprvl. $SVNS

The burden of Severe AUD is staggering & urgent. 📊 40M w/ AUD across US UK EU4.➡️ ~13M w/ Severe AUD.💀 300K+ deaths/yr.💷 £27.4B/yr in England alone. @Solvonis_Tx is advancing SVN‑001 — a Phase 3 treatment aiming to change this. 🔗 $SVNS #AUD #SVN001

Solvonis (LSE: $SVNS) is pleased to announce that @Singer_CM has initiated research coverage. The note, “Psyching Up for Success”, is authored by Dr. Karl Keegan, Head of Life Sciences Research. Avail to institutional investors now; public next week.

At Solvonis (LSE: SVNS), USPTO has allowed a core patent (No. 18/838,986) for novel #CNS compounds in our #AI-enabled discovery prgm. -No objections.-Indications: depression, stimulant use disorder.-US exclusivity to ≥2043. $SVNS #Biotech #MentalHealth .